Literature DB >> 27879269

Basophils Promote Tumor Rejection via Chemotaxis and Infiltration of CD8+ T Cells.

Ibrahim M Sektioglu1, Rafael Carretero1, Nadja Bulbuc1, Tobias Bald2, Thomas Tüting2, Alexander Y Rudensky3, Günter J Hämmerling4.   

Abstract

Elevated numbers of regulatory T cells (Treg) in patient tumors are known to inhibit efficient antitumor T-cell responses. To study the mechanisms controlling tumor rejection, we assessed different mouse models for Treg depletion. In Foxp3DTR knock-in mice, about 99% Treg depletion was achieved, resulting in complete rejection of transplanted HCmel12 melanomas in a CD8+ T-cell-dependent way. In contrast, about 90% Treg depletion obtained in BAC transgenic Foxp3.LuciDTR4 mice failed to induce complete rejection of HCmel12 melanomas, demonstrating that residual Tregs were able to control CD8+ T-cell responses against the tumor. Ninety-nine percent of Treg depletion provoked drastic changes in the tumor microenvironment, such as strong infiltration of CD8+ T cells and basophils. Intratumoral basophils enhanced CD8+ T-cell infiltration via production of chemokines CCL3 and CCL4; antibody-based blocking of these chemokines inhibited CD8+ T-cell infiltration. Therapeutic induction of basophilia by IL3/anti-IL3 antibody complexes, combined with transfer of CD8+ T cells, resulted in enhanced T-cell infiltration and tumor rejection. Our study identifies a critical role basophils play in tumor rejection and that this role can be exploited for therapeutic intervention. Cancer Res; 77(2); 291-302. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27879269     DOI: 10.1158/0008-5472.CAN-16-0993

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Frontline Science: Superior mouse eosinophil depletion in vivo targeting transgenic Siglec-8 instead of endogenous Siglec-F: Mechanisms and pitfalls.

Authors:  Eva Knuplez; Rebecca Krier-Burris; Yun Cao; Gunther Marsche; Jeremy O'Sullivan; Bruce S Bochner
Journal:  J Leukoc Biol       Date:  2020-03-05       Impact factor: 4.962

Review 2.  The role of basophils as innate immune regulatory cells in allergy and immunotherapy.

Authors:  Salvatore Chirumbolo; Geir Bjørklund; Andrea Sboarina; Antonio Vella
Journal:  Hum Vaccin Immunother       Date:  2018-01-18       Impact factor: 3.452

3.  Clinical Outcomes and Immune Metrics in Intratumoral Basophil-Enriched Gastric Cancer Patients.

Authors:  Xudong He; Yifan Cao; Yun Gu; Hanji Fang; Jieti Wang; Xin Liu; Kunpeng Lv; Kuan Yu; Yuchao Fei; Chao Lin; Hao Liu; Heng Zhang; He Li; Jiejie Xu; Ruochen Li; Hongyong He
Journal:  Ann Surg Oncol       Date:  2021-03-18       Impact factor: 5.344

4.  C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer.

Authors:  Songyang Wu; Hongyong He; Hao Liu; Yifan Cao; Rochen Li; Heng Zhang; He Li; Zhenbin Shen; Jing Qin; Jiejie Xu
Journal:  Oncoimmunology       Date:  2018-03-06       Impact factor: 8.110

5.  Prognostic value of pretreatment circulating basophils in patients with glioblastoma.

Authors:  Lingnan Zheng; Min Yu; Shuang Zhang
Journal:  Neurosurg Rev       Date:  2021-03-25       Impact factor: 3.042

Review 6.  Basophils as a potential therapeutic target in cancer.

Authors:  Jicheng Zhang; Hanlin Yin; Qiangda Chen; Guochao Zhao; Wenhui Lou; Wenchuan Wu; Ning Pu
Journal:  J Zhejiang Univ Sci B       Date:  2021-12-15       Impact factor: 3.066

7.  Eosinophils Decrease Pulmonary Metastatic Mammary Tumor Growth.

Authors:  Rachel A Cederberg; Sarah Elizabeth Franks; Brennan J Wadsworth; Alvina So; Lisa R Decotret; Michael G Hall; Rocky Shi; Michael R Hughes; Kelly M McNagny; Kevin L Bennewith
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

8.  IgG Autoantibodies Against IgE from Atopic Dermatitis Can Induce the Release of Cytokines and Proinflammatory Mediators from Basophils and Mast Cells.

Authors:  Remo Poto; Isabella Quinti; Gianni Marone; Maurizio Taglialatela; Amato de Paulis; Vincenzo Casolaro; Gilda Varricchi
Journal:  Front Immunol       Date:  2022-05-31       Impact factor: 8.786

9.  Enriching CCL3 in the Tumor Microenvironment Facilitates T cell Responses and Improves the Efficacy of Anti-PD-1 Therapy.

Authors:  Tae Gun Kang; Hyo Jin Park; Jihyun Moon; June Hyung Lee; Sang-Jun Ha
Journal:  Immune Netw       Date:  2021-06-17       Impact factor: 6.303

Review 10.  The Janus Face of IL-33 Signaling in Tumor Development and Immune Escape.

Authors:  Mi-Ran Choi; Jeffrey A Sosman; Bin Zhang
Journal:  Cancers (Basel)       Date:  2021-06-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.